RxDoctor Payments Data

Jacqueline Albiez-Dobransky, NP

Psychiatric/Mental Health · South Bend, INNPI 1447928007

Payments from drug & device makers

$517in general payments, 2019–2025

Across 19 payments — averaging $27.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$202
  • Otsuka America Pharmaceutical, Inc.$125
  • AbbVie$87
  • Axsome Therapeutics, Inc.$26
  • Sage Therapeutics, LLC$22
  • Ironshore Pharmaceuticals Inc.$19
  • plus $36 from 3 others

What the payments were for

  • Food & beverage$46189%
  • Education$5511%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$517 in reported general payments places this provider in the 45th percentile of 729 psychiatric/mental health providers in Indiana.

See all psychiatric/mental health providers in Indiana

Medicare billing

Part B allowed, 2024
$26,272
Medicare patients
104
Services billed
322

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RexultiBrexpiprazole31$45,106
CaplytaLumateperone Tosylate18$30,817
Effexor XrVenlafaxine Hcl24$15,261
TrintellixVortioxetine Hydrobromide19$11,023
Aripiprazole112$9,149
Asenapine Maleate12$4,180
Olanzapine38$3,210
Lurasidone Hcl36$3,163
Hydroxyzine Hcl121$2,641
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine80$2,314
Duloxetine Hcl126$2,201
Bupropion XlBupropion Hcl98$1,828
Buspirone Hcl133$1,670
Mirtazapine77$1,524
Quetiapine Fumarate72$1,460

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Rexulti$125$45,10631 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$202$30,81718 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 729 psychiatric/mental health providers in Indiana.

Other psychiatric/mental health in South Bend

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →